IRB #

IRB00009241

Title

Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to see whether treatment with a drug called Pazopanib after surgery for kidney cancer and metastases will increase the time without cancer returning.

Medical Condition(s)

Metastatic Renal Cell Carcinoma

Eligibility Criteria

*Must be 18 years or older
*Patient must have pathology showing confirmed renal cell carcinoma with clear cell. Metastatic disease also needs to be confirmed through pathology
*Must have undergone surgery to remove kidney cancer at any time in the past.
*Must have undergone surgery to remove all known locations of metastases successfully 2 to 12 weeks before beginning study.
*No prior treatment for renal cell carcinoma.
*No evidence of disease on a CT or MRI within 4 weeks before beginning study.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 10 years.

Minors Included

No

Contact

Deidre Nauman
naumand@ohsu.edu
503-494-3078

Sponsor

Eastern Cooperative Oncology Group (ECOG)

Recruitment End

08/22/2017

Compensation Provided

No